Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment
An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how findings from Liu et al (Lancet, 2024) inform the evolving treatment landscape.
Video Player is loading.
Video content above is prompted by the following:
- With emerging developments in the use of systemic immunotherapy for recurrent/metastatic NPC, what insights can you share from the perspective of a radiation oncologist?
- How do findings from inform the treatment landscape?
Recent Videos
Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging
Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology
Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology
Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC
Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease
JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN
Future Outlooks for CAR T in Early R/R Multiple Myeloma
Clinical Perspectives for the Treatment of R/M NPC
Treatment Paradigms in R/M NPC: The Role of Systemic Immunotherapy
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting
Related Content
